Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07399678 · ClinicalTrials.gov registry record · Phase 1
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes, sponsored by Alveus Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT07399678: Recruiting Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes, sponsored by Alveus Therapeutics.
NCT07399678 is a Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes that is actively recruiting participants, run by Alveus Therapeutics. The registered enrollment target is 180 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07399678, a Phase 1 study of Overweight or Obese Adults and Overweight or Obese, Type 2 Diabetes, is actively recruiting participants, sponsored by Alveus Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Primary Outcome
Incidence of treatment emergent adverse events (TEAEs)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALV-100
Study Locations (1)
Florida
- Clinical Pharmacology of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT07399678 shows while recruiting
NCT07399678 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher).
The record links to 2 conditions, with Overweight or Obese Adults appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07399678 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07399678 about?
NCT07399678 is a clinical study titled "Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D". A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
What is the current status of trial NCT07399678?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2025-12-29. Estimated completion is 2027-09.
What conditions does trial NCT07399678 study?
This clinical trial studies the following conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes.
What interventions are being tested in trial NCT07399678?
The interventions under investigation include: Placebo (DRUG), ALV-100 (DRUG).
Who is sponsoring clinical trial NCT07399678?
This trial is sponsored by Alveus Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07399678 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight or Obese Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07399678's enrollment target sits among peer trials
180 300th of 2000 higher than 1,690 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI